Pricing Log in Create free account
Monday 2 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

TWST Healthcare Biotechnology

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue
+23.2%
EPS
−264.7%
Free cash flow
−7.23%
Total debt
0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%
Market cap
$10.1B
P/E
0.0×
Fwd P/E
−91.4×
Dividend yield
—
F-score
4/9
Altman Z
3.44
Beneish M
−2.30
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Twist Bioscience Corporation 10-K filed Nov 17, 2025

Fiscal year 2025 · Period ended Sep 30, 2025 · Filed · accepted 7:31 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Nov 18, 2024: 6 added · 31 removed · 50 modified; 3 with only figures updated

  1. Modified

    At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials, academic research and data storageacademic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.